Early fibrinogen degradation coagulopathy: A predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis
Authors:
- 1 April 2015
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 351 (1-2) , 109-114
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Do Not Wait, Act NowStroke, 2007
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- Classification and Pathogenesis of Cerebral Hemorrhages After Thrombolysis in Ischemic StrokeStroke, 2006
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.Stroke, 1994
- Thrombolytic Agents in the Treatment of StrokeClinical Neuropharmacology, 1990